Sarah A. Tersey, PhD
Adjunct Associate Research Professor of Pediatrics
Dr. Sarah Tersey received her bachelor's from Colorado State Univeristy and her PhD from the University of Massachuesetts. Dr. Tersey subsequently completed a postdoctoral fellowship at Harvard Medical School and Massachuesetts General Hospital, as well as a diabetes fellowship at the University of Virginia. She joined the research faculty at IUSM in 2008. Dr. Tersey is currently an Associate Research Professor of Pediatrics. Dr. Tersey is the Associate Director of the Islet and Physiology Core and co-Associate Director of the Translation Core; and serves on the Indiana Diabetes Research Center (IDRC) Exectuive Committee.
Hernandez-Perez M, Chopra G, Fine J, Conteh AM, Anderson RM, Linnemann AK, Benjamin C, Nelson JB, Benninger KS, Nadler JL, Maloney DJ, Tersey SA, Mirmira RG.
Diabetes. 2017 Aug 25. pii: db170215. doi: 10.2337/db17-0215. [Epub ahead of print]
Tersey SA, Nelson JB, Fisher MM, Mirmira RG.
J Vis Exp. 2016 Dec 21;(118). doi: 10.3791/54838.
Tersey SA, Maier B, Nishiki Y, Maganti AV, Nadler JL, Mirmira RG.
Mol Cell Biol. 2014 Oct 1;34(19):3735-45. doi: 10.1128/MCB.00157-14. Epub 2014 Jul 28.
Tersey SA, Nishiki Y, Templin AT, Cabrera SM, Stull ND, Colvin SC, Evans-Molina C, Rickus JL, Maier B, Mirmira RG.
Diabetes. 2012 Apr;61(4):818-27. doi: 10.2337/db11-1293.
Ped-Endocrinology Basic Res
R4 W155 PENB
The primary goal of my research focuses on understanding the molecular pathways that play a role in the development of diabetes. Specifically, pathways that include the enzymes 12-lipoxygenase and deoxyhypusine synthase. By using inhibitors against the pathways or creating genetic deletions of either of these genes, I have shown that diabetes can be prevented. A second major focus of my research is the development of biomarkers that will best predict the likelihood of any one individuals risk to develop type 1 diabetes. Within this concept, I demonstrated that the dysfunction of the pancreatic islet precedes the onset of type 1 diabetes. This research has changed the standard dogma of the islet as a silent bystander to the immune system, to the new way to thinking that the islet is a major player in its own demise during the pre-course of type 1 diabetes. We have also utilized this concept and developed a novel biomarker to predict diabetes in both a mouse model of type 1 diabetes and human individuals with new onset type 1 diabetes.
Association for Clinical & Translational Sciences